JP7460639B2 - 血液癌を治療するための併用療法 - Google Patents

血液癌を治療するための併用療法 Download PDF

Info

Publication number
JP7460639B2
JP7460639B2 JP2021539498A JP2021539498A JP7460639B2 JP 7460639 B2 JP7460639 B2 JP 7460639B2 JP 2021539498 A JP2021539498 A JP 2021539498A JP 2021539498 A JP2021539498 A JP 2021539498A JP 7460639 B2 JP7460639 B2 JP 7460639B2
Authority
JP
Japan
Prior art keywords
pyridin
axl
pyrazol
bcl
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021539498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022501434A (ja
JP2022501434A5 (enExample
Inventor
ザイホイ・ジャン
シャオヤン・ジアン
カタリーナ・ローテ
シャオジア・ニウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signalchem Lifesciences Corp
Original Assignee
Signalchem Lifesciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signalchem Lifesciences Corp filed Critical Signalchem Lifesciences Corp
Publication of JP2022501434A publication Critical patent/JP2022501434A/ja
Publication of JP2022501434A5 publication Critical patent/JP2022501434A5/ja
Application granted granted Critical
Publication of JP7460639B2 publication Critical patent/JP7460639B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021539498A 2018-09-18 2019-09-18 血液癌を治療するための併用療法 Active JP7460639B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862732816P 2018-09-18 2018-09-18
US62/732,816 2018-09-18
PCT/US2019/051764 WO2020061216A1 (en) 2018-09-18 2019-09-18 Combination therapy for treating blood cancer

Publications (3)

Publication Number Publication Date
JP2022501434A JP2022501434A (ja) 2022-01-06
JP2022501434A5 JP2022501434A5 (enExample) 2022-09-28
JP7460639B2 true JP7460639B2 (ja) 2024-04-02

Family

ID=68104787

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021539498A Active JP7460639B2 (ja) 2018-09-18 2019-09-18 血液癌を治療するための併用療法

Country Status (13)

Country Link
US (1) US12097194B2 (enExample)
EP (1) EP3852766B1 (enExample)
JP (1) JP7460639B2 (enExample)
KR (1) KR102764125B1 (enExample)
CN (1) CN112739349B (enExample)
AU (1) AU2019343044B2 (enExample)
BR (1) BR112021005054A2 (enExample)
CA (1) CA3110901C (enExample)
IL (1) IL281439B2 (enExample)
MX (1) MX2021003062A (enExample)
SG (1) SG11202101955SA (enExample)
TW (1) TWI824010B (enExample)
WO (1) WO2020061216A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
KR20200108301A (ko) 2018-01-10 2020-09-17 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
KR20220098755A (ko) 2019-11-05 2022-07-12 애브비 인코포레이티드 나비토클락스를 사용한 골수섬유증 및 mpn 관련 장애 치료에 사용하기 위한 투약 레지멘
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑ｈｄａｃ６抑制劑及其用途
WO2025170888A1 (en) * 2024-02-05 2025-08-14 Signalchem Lifesciences Corporation A combination of the axl inhibitor slc-391 and a pd-1 inhibitor for use in the treatment of blood cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540577A (ja) 2005-05-12 2008-11-20 アボット・ラボラトリーズ アポトーシス促進剤
JP2017501981A (ja) 2013-11-27 2017-01-19 シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｔａｍファミリーキナーゼ阻害剤としてのアミノピリジン誘導体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
PL2387395T3 (pl) 2009-01-16 2015-03-31 Rigel Pharmaceuticals Inc Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowym
ES2603129T3 (es) 2010-11-23 2017-02-23 Abbvie Ireland Unlimited Company Métodos de tratamiento utilizando inhibidores selectivos de Bcl-2
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
IL286427B2 (en) * 2014-01-28 2024-08-01 Mayo Found Medical Education & Res Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease
US20170137426A1 (en) * 2014-03-28 2017-05-18 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as axl inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540577A (ja) 2005-05-12 2008-11-20 アボット・ラボラトリーズ アポトーシス促進剤
JP2017501981A (ja) 2013-11-27 2017-01-19 シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｔａｍファミリーキナーゼ阻害剤としてのアミノピリジン誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia，Cancer Discovery，2014年，Vol.4, No.3，p.362-375

Also Published As

Publication number Publication date
TW202023554A (zh) 2020-07-01
IL281439A (en) 2021-04-29
CN112739349B (zh) 2024-03-01
MX2021003062A (es) 2021-05-27
CN112739349A (zh) 2021-04-30
TWI824010B (zh) 2023-12-01
JP2022501434A (ja) 2022-01-06
WO2020061216A1 (en) 2020-03-26
EP3852766A1 (en) 2021-07-28
BR112021005054A2 (pt) 2021-06-08
EP3852766B1 (en) 2024-05-08
US20220031685A1 (en) 2022-02-03
SG11202101955SA (en) 2021-03-30
CA3110901A1 (en) 2020-03-26
CA3110901C (en) 2024-01-02
KR20210061356A (ko) 2021-05-27
IL281439B2 (en) 2025-02-01
AU2019343044A1 (en) 2021-03-18
US12097194B2 (en) 2024-09-24
IL281439B1 (en) 2024-10-01
AU2019343044B2 (en) 2025-03-06
KR102764125B1 (ko) 2025-02-07

Similar Documents

Publication Publication Date Title
JP7460639B2 (ja) 血液癌を治療するための併用療法
JP7476380B2 (ja) 血液学的障害を治療するための化合物および組成物
JP2023520333A (ja) Ｅｉｆ４ａ阻害剤組み合わせ
JP6180420B2 (ja) 増殖性疾患の治療のためのｈｓｐ９０阻害剤と組み合わせた２−カルボキサミドシクロアミノウレア誘導体
JP2020512343A (ja) 血液疾患を処置するための化合物及び組成物
AU2017220738A1 (en) Carboxamide derivatives useful as RSK inhibitors
TW201244719A (en) Combinations of kinase inhibitors for the treatment of cancer
BR112021002632A2 (pt) compostos e composições de ureia como inibidores de smarca2/brm atpase
TW202031253A (zh) 治療黑色素瘤的藥物組合
WO2013091502A1 (en) Tri-heterocyclic derivatives, preparation process and uses thereof
CA2608171C (en) Use of quinolinone compounds for treating drug resistant cancers
KR20220101656A (ko) 병용 의약
US9549921B2 (en) Heterocyclic compounds and methods of use thereof for the treatment of hepatitis C
CN112237579A (zh) 药物组合及其用途
HK40042345A (en) Combination therapy for treating blood cancer
HK40042345B (zh) 用於治疗血癌的组合疗法
JP2026507092A (ja) 健康状態の治療のための小分子を作製および使用するための組成物および方法
HK40035225A (en) Pharmaceutical combination and use thereof
HK1110477B (en) Methods for treating drug resistant cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240312

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240321

R150 Certificate of patent or registration of utility model

Ref document number: 7460639

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150